Nomura Holdings Inc Fate Therapeutics Inc Transaction History

Nomura Holdings Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $2.27 Million - $5.49 Million	230,554 Added 152.47%	381,770 $3.85 Million
Q3 2022 Nov 15, 2022	BUY	$21.04 - $36.06 $2.42 Million - $4.15 Million	114,967 Added 317.16%	151,216 $3.41 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $644,507 - $1.54 Million	36,249 New	36,249 $909,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $152,323 - $246,026	-2,570 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $432,417 - $594,903	-6,430 Reduced 71.44%	2,570 $224,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $649,440 - $1.06 Million	9,000 New	9,000 $741,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $143M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.